文献速递神经肌肉病

脊髓延髓肌萎缩症临床前进展的生物标志物分析

Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy.
PubMed 文献 · Neurology · 2018-03-23

研究纳入40例基因确诊的脊髓延髓肌萎缩症(SBMA)患者、48例健康对照、25例肌萎缩侧索硬化(ALS)患者和20例帕金森病(PD)患者,分析健康体检中生化指标的纵向变化。SBMA患者血清肌酐在肌无力起病前超过10年即开始下降,起病时平均血清肌酐浓度为0.56 mg/dL,健康对照末次评估为0.88 ± 0.10 mg/dL;ALS和PD患者未见这些临床前生物标志物变化。

要点

  • SBMA患者血清肌酐在肌无力起病前超过10年即开始下降。
  • SBMA起病时平均血清肌酐0.56 mg/dL,健康对照末次评估0.88 ± 0.10 mg/dL。
  • 临床前SBMA患者丙氨酸转氨酶和天冬氨酸转氨酶呈升高趋势。

核心结论

  • 研究提示血清肌酐在临床症状起病前即开始下降,是SBMA临床前疾病进展和治疗疗效的生物标志物。

研究设计与样本

  • 分析健康体检中获得的生化参数在SBMA诊断前后的纵向变化,使用线性混合模型估计临床标志物自肌无力起病起跨年份的轨迹,并与男性健康对照及ALS和PD患者比较。
  • 2014年10月至2017年10月纳入40例基因确诊的SBMA患者、48例健康对照、25例ALS患者和20例PD患者。
  • SBMA患者评估数据覆盖17.3 ± 7.5年,其中临床前阶段11.4 ± 7.1年。
  • 使用Kaplan-Meier曲线分析血清肌酐水平与症状起病的关系。

主要发现

  • SBMA患者血清肌酐下降发生在起病前超过10年。
  • SBMA患者肌无力起病时平均血清肌酐浓度为0.56 mg/dL,健康对照末次评估为0.88 ± 0.10 mg/dL。
  • SBMA临床前阶段血清丙氨酸转氨酶和天冬氨酸转氨酶呈升高趋势。
  • 这些临床前生物标志物变化在ALS或PD患者中均未观察到。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify a candidate biomarker reflecting biological changes during the preclinical progression of spinal and bulbar muscular atrophy (SBMA). METHODS: We analyzed longitudinal changes in biochemical parameters obtained during health examinations before and after the diagnosis of SBMA. We estimated trajectories of clinical markers across years from the onset of weakness using linear mixed models and compared these trajectories with those estimated for male healthy controls and patients with amyotrophic lateral sclerosis (ALS) and Parkinson disease (PD). Moreover, we examined the relationship between serum creatinine level and the onset of symptoms using Kaplan-Meier curves. RESULTS: Between October 2014 and October 2017, we enrolled 40 patients with genetically confirmed SBMA, 48 healthy controls, 25 patients with ALS, and 20 patients with PD. In patients with SBMA, we evaluated the patients' data for a period of 17.3 ± 7.5 years, including 11.4 ± 7.1 years of preclinical phase. Decreases in serum creatinine occurred >10 years before the onset. The mean serum creatinine concentration was 0.56 mg/dL at the onset of weakness in patients with SBMA compared to 0.88 ± 0.10 mg/dL on final evaluation in healthy controls. Serum levels of alanine transaminase and aspartate transaminase showed tendencies to increase in preclinical SBMA. These preclinical changes of biomarkers were not observed in either ALS or PD. CONCLUSIONS: Our findings suggest that serum creatinine begins to decrease before the onset of clinical symptoms and is a biomarker for disease progression and the efficacy of therapeutics in preclinical SBMA.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Hijikata Y, Hashizume A, Yamada S, et al. Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy. Neurology. 2018. PMID: 29572281. doi:10.1212/WNL.0000000000005360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。